SlideShare a Scribd company logo
A Promise to Precision in Clinical Trials
Vision / Mission
• To be the preferred, trusted and valued Clinical development partner
for global pharmaceutical & biotechnology companies.
• Known as a Integrated health service provider of choice.
• Deliver sophisticated clinical research services without compromising quality or timelines.
A Promise to Precision in Clinical Trials
A Promise to Precision in Clinical Trials
Value Based Leadership : Our mission outlines the value that provides the
foundation to perform as a Global service provider and as individual
employees so that we can continue to put the needs of the Customers we serve first.
Integrity : We do what is right.
a) We are committed to conduct our business with individual and organizational Integrity.
b) We comply with Local and International laws.
c) We are reliable, honest and trustworthy in our dealings.
Responsibility : We hold ourselves accountable for our actions.
a) We take personal responsibility in everything that we do and we lead by example.
b) We treat our Organization's reputation as our own.
c) We are committed to a culture of shared responsibility that promotes high performance.
Our Core Values
A Promise to Precision in Clinical Trials
a) Speed :
We will speed you to the next milestone, while avoiding the bumps in the road.
Because the faster you reach each milestone, the faster your compound can be
advanced to next stage.
b) Quality :
We are passionate about what we do and want our name to stand for Excellence.
We are determined to be an example that the industry aspires to follow.
c) Customer Focus :
We build long lasting, collaborative relationship with our customers and work with
them as thought partners.
c) Disciplined Timelines :
We value the importance of time and adhere to our commitments.
Your Preferred Partner of Choice – Why ?
A Promise to Precision in Clinical Trials
Leading Global Clinical Research
organization accelerating the Drug
Development.
 Established in Sept. 2004.
 Central Headquarters at Hyderabad, India.
 Facilities in 3 Countries (India, Mexico and Thailand)
and more than 400+ professionals operating worldwide.
 Fully Compliant with ICH GCP, ICMR, Mexican COFEPRIS,
Thai FDA and Schedule – Y Guidelines.
 Combined Clinical bed Strength of 500 +, supported by 22
LC-MS/MS machines, with more than 275+ validated analytical
methods.
 More than 50,000 active study participants in global
database.
 Over 80% business repeat business.
Overview
A Promise to Precision in Clinical Trials
Experience:
 8+ years of Biopharmaceutical experience for Global clients.
 50+ Pharma and Biotech Sponsors all over the globe.
 1550+ successful clinical studies.
Consistency:
 Less than 5% attrition YOY.
 More than 80% Repeat Business.
Global Footprints :
 Operations : India, Mexico and Thailand.
 Offices in India, USA, Mexico and Thailand.
Overview…
2007
2008
2009
2010
2011
2013
ANVISA- Brazil : ANVISA Certification.
US-FDA : October.
US-FDA : March.
UK-MHRA : February.
FRENCH-AFSSAPS : June.
ANVISA- Brazil : October.
US-FDA : October.
US-FDA : May.
US-FDA : June.
US-FDA : February.
US-FDA : March.
US-FDA : October.
Turkey-MOH : December.
ANVISA- Brazil : August.
UK-MHRA : October.
ANVISA – Brazil : August
USFDA : August
Global Regulatory Accreditations - Milestones
A Promise to Precision in Clinical Trials
NABL : Accreditation.
ANVISA – Brazil : October.
USFDA : October.
2012
Capabilities / Expertise @ AXIS
PK / PD studies
 Bioequivalence / Bioavailability studies
 Pharmacokinetic / Pharmacodynamic
studies in Healthy subjects
 Special / Patient Population studies.
 Food effect / Drug – Drug Interaction
studies.
 Proof of Concept studies.
 End-to End Service
 - Protocol to Report
 Project Management
 Final submission Report (eCTD / ICH E3)
Clinical Research
 Phase II- IV trials
 PK / PD Studies in patients
 Feasibility Studies
 Project Planning and Setup
 Study Design and Protocol Writing
 Regulatory Approvals
 Design & Development of CRF / eCRF
 Project Management
 Site/Investigator Identification and
Selection
 Site Monitoring
 Site Management
 Quality Assurance/Audit Services
A Promise to Precision in Clinical Trials
Biostatistics & Medical Writing
 Sample Size and Power Calculation
 Medical writing and literature search
 Providing Statistical Inputs during
Protocol Designing
 Randomization
 Statistical Analysis Plan (SAP)
 SAS Programming and Validation
 Interim Analysis
 Statistical Report
Clinical Data Management
 Data Management Plan
 Database Design & Development
 Double-Data Entry
 Query Management
 Medical Coding, SAE Data Reconciliation
 Edit, Validation and Design check
programming
 Data Validation
 Data Cleaning
 Quality Control and Data Quality Audits
 Database Lock and Export to SAS
 Clean Data Files
 Project Data Archival and Storage
Capabilities / Expertise @ AXIS …
A Promise to Precision in Clinical Trials
Capabilities / Expertise @ AXIS …
Stand Alone Services
 Regulatory Services.
 Central Reference Lab Services.
 Bio Analytical Services.
 Metal Ion analysis.
 Biostatistical & Medical Writing.
 Quality Assurance.
 Clinical Data Management.
A Promise to Precision in Clinical Trials
Regulatory Inspections & Approvals
 Successfully completed over 38 regulatory audits by Indian and International regulatory bodies
 Completed 50+ National and International sponsor audits
Canada
Turkey MOH
Credentials
WHO
Australia
US FDA
UK MHRA
Brazil ANVISA
France AFSSAPS
Mexico MOHNABL India
South Africa
Product Approvals
A Promise to Precision in Clinical Trials
Malaysia
US, 973
Europe, 300
Brazil, 67
Canada, 101
Australia, 62
Korea, 25
WHO, 10
Turkey, 12
Russia, 3
India, 3
Studies Completed = 1550+
Bio-studies Experience : Geographical Submissions
A Promise to Precision in Clinical Trials
Clinical Pharmacology
India
 292 Beds arranged in 7 study areas in 2 locations .
 1,90,000 sq. ft area.
 7 Intensive Care Units with cardiac monitoring.
 Audited &/or accredited by US FDA, UK MHRA, Brazilian
ANVISA, India (DCGI), AFSSAPS, NABL and ISO 9001:2000.
 World-class infrastructure to support clinical activities.
 18 LC-MS/MS & 1 ICP-OES for bioanalysis.
 Capacity to handle approx. 2000 Clinical dosings / month.
 Capability to analyze approx. 35,000 samples / month.
A Promise to Precision in Clinical Trials
Clinical Pharmacology
Mexico
 100 Beds arranged in 3 study areas.
 Intensive Care Units with cardiac monitoring.
 Dedicated Clinical Reference Lab.
 Approved by Cofepris (Mexican Regulatory
Agency) for Clinical and Bioanalytical operations.
 World-class infrastructure to support the Latin
America market & other Regulated markets.
 4 LC-MS/MS for bioanalysis.
 Independent Project Management Group.
A Promise to Precision in Clinical Trials
Clinical Pharmacology
Thailand
 72 Beds arranged in 6 study areas.
 Hospital setup
 Intensive Care Units with cardiac monitoring.
 World-class infrastructure to support clinical activities in SE
Asian countries.
 Capabilities to conduct and monitor the Phase II – IV studies
A Promise to Precision in Clinical Trials
 Testing @ ACRL
 Hematology and Coagulation Assays
 Biochemistry
 Clinical Pathology
 Immunoassays
 Histopathology
 NABL (National Accreditation Board for Testing and
Calibration Laboratories) accredited laboratory
 Audited by Brazil ANVISA & UK MHRA
 Services for Clinical Trials having multiple sites & CROs
(Stand Alone Services also offered).
Clinical Reference Laboratory
A Promise to Precision in Clinical Trials
 18 LC-MS/MS
(SCIEX API 2000, 3000, 3200, 4000, 4000Q and 5000)
 5 HPLC-UV/Fluorescent Detectors.
 1 ICP-OES for Trace Metal Analysis.
 275+ validated assays.
 Quantitative analysis of parent drugs and their
metabolites in a variety of biological matrices.
 Networked Chromatographic Data Management
(Scientific Data Management System)
 Solid Phase Extraction Systems.
 Nitrogen Evaporators.
 Capability to analyse > 35,000 samples/month.
Bioanalytical Lab
A Promise to Precision in Clinical Trials
 Critical assays developed First-in-Asia for small molecules
 Conjugated Estrogen
 Esterified Estrogens
 Estradiol
 Ethinyl Estradiol & Levonorgestrol
 Many combinations of Oral Contraceptives
 First-in-world assays for small & large molecules
 Loteprednol in Aqueous Humor
 Dexamethasone in Aqueous Humor
 Testosterone in serum
 Critical assay in development and validation stage for large
molecules
 Insulin
 Glucagon
 Enoxaparin
Bioanalytical Lab …
A Promise to Precision in Clinical Trials
Expertise (Formulations & Therapeutic Areas)
Formulations
 Oral Solids – Capsules, Tablets,
Softgels, Granules, ODT, ODP,
Modified Release
 Liquid Orals
 Parenterals
 Transdermal patches
 Topical Gel
 Cream
 Inhalers
 Nasal Sprays
Therapeutic Areas
 Antibiotic/ Antimicrobial
 Antidepressant
 Antiepileptic
 Antiretroviral
 Hormone
 Hypoglycemic agents
 Lipid lowering agents
 Muscle relaxants
 NSAIDs
 Narcotics
 Oral contraceptive
 Psychotropic agents
A Promise to Precision in Clinical Trials
Quality Systems @ AXIS
 A 30 member dedicated team reporting to QA Head.
 Quality Control (QC) Procedures in place apart from Quality Assurance (QA) Procedures.
 All activities are subjected to rigorous review for Quality Assurance including
 Clinical (over 50 SOP’s)
 Bio-analytical
 PK / Stats / Reporting
 Internal Audits by QA team for Area Specific SOP compliance.
 In-house capabilities to perform Site Audits, Systems / Process Audit, Vendor Audit.
 Document Audits (Protocol, Clinical Study Report & essential Clinical Trial documents).
 All QA systems are compliant with all applicable local & international regulations.
A Promise to Precision in Clinical Trials
Clinical Experience and Capabilities
 Summary Protocol / Synopsis
 Study Feasibility Analysis
 Study Design
 Medical Writing and Protocol Development
 Project Planning and Setup
 Regulatory Approvals
 Design & Development of CRF / eCRF
 Site/Investigator Identification and Selection
 Site Management
 Site Monitoring
 Project Management
 Clinical Data Management
 Clinical Study Reports
 Quality Assurance / Audit Services
A Promise to Precision in Clinical Trials
Clinical Research (Phase II –IV)
 Phase 2-4 Clinical Trials (New Chemical Entities)
 >150 sites
 >200 Investigators
 Oncology, CNS, Cardiology, Gastrointestinal, Orthopedic,
Ophthalmology, Endocrinology & Metabolism
 505(b)(2) Clinical Studies.
 Clinical End Point Studies.
 Patient Population PK Studies,
A Promise to Precision in Clinical Trials
Experience – Clinical Trials
Sr.
No.
Therapeutic
Segment
Study phase Patients /
Sites
Current status
1. Allergic
conjunctivitis
Phase III 514; 10 sites Recruitment expected to
complete in 90 days
2. Schizophrenia Clinical PK
study
28; 2 sites Recruitment completed within 50
days
3. Schizophrenia Clinical PK
study
40; 3 sites Recruitment completed within 81
days
4. Schizophrenia Clinical PK
study
26; 4 sites Recruitment completed within 79
days
5. Epilepsy Clinical PK
study
34; 2 sites Recruitment completed within
170 days
6. Anemia in CKD Phase IIa 180; 8 sites Recruitment completed within
120 days
7. Schizophrenia Clinical PK
study
42; 4 sites Recruitment completed within 75
days
A Promise to Precision in Clinical Trials
CNS
13%
Oncology
21%
Gastroenetrology
5%
Dermatology
8%
Cardiology
11%
Urology
5%
Ophthalmology
32%
Respiratory
5%
Study Pipeline
A Promise to Precision in Clinical Trials
AXIS’ Investigator & Sites relationship
Clinical Research – Potential Investigator Database
A Promise to Precision in Clinical Trials
Clinical Data Management & Biostatistics
 Oracle Clinical® v4.6 with Remote Data Capture
 Project Specific Clinical Data Management Plan
 Customized Database Design & Development
 Independent Double-Data Entry
 Query Management
 Medical Coding, SAE Data Reconciliation
 Edit, Validation and Design check
 Data Validation
 Data Cleaning
 Quality Control and Data Quality Audits
 Database Lock and Export to SAS
 Documentation CDM Report
A Promise to Precision in Clinical Trials
 Project Management Group (PMG) : Dedicated Project Managers are assigned to each
Client to ensure the timely execution of the projects at AXIS Clinicals. Back up
Project Managers help to maintain the continuity.
 QA Department : 30 experienced personnel to maintain Quality of the highest
standards.
 HR / Training Department: A team of 4 people in the Training Department ensures the
Inductions, On Job Trainings, Refresher Trainings and arranging External
Trainings for the AXIS employees.
 Validation : AXIS has a dedicated team for Validation and the maintenance of
Scientific equipment is done on a regular basis by the GLP Engineers.
 Pharmacy : Each of the Clinical Units of AXIS has Dedicated Pharmacists for the
IMP Management
Support Teams at Axis
A Promise to Precision in Clinical Trials
Management Team
Michael Padvaiskas Ackerman
President - Mexico Operations
Dr. A. Jayachandra Reddy
Sr. V.P – Clinical Pharmacology
Dr. Yati Chugh
Chief Executive Officer
B. Phani Bhushana Reddy
Sr. V.P – Bioanalytical Operations
A Promise to Precision in Clinical Trials
Someswar Korla
Head – PK/Stats/Medical Writing
Sathish Munaga
Head – Quality Assurance
Abhijit Chaudhari
Director – Business Dev. (India / ROW)
Sidharth Mishra
Director – Business Dev. (U.S.A)
Dr. Subhra Lahiri
AVP – Clinical Research
A Promise to Precision in Clinical Trials
Dr. Kshitij Soni
Director – ASEAN Operations
 End to End service provider with experienced Clinical research professionals and Excellent
infrastructure.
 Impressive Accreditations from International Regulatory Bodies.
 Successful Regulatory Inspections track record.
 Teams with Rich professional Experience.
 Expertise in various Therapeutic segment.
 Access to Patient’s in major therapeutic areas.
 Fast and excellent Turn around time.
 Competitive Pricing as compared to Industry Peers.
 AXIS can help you to file FTF application in 18 – 20 days.
 Top 5 International Generic companies among the list of Client’s.
The AXIS Edge
A Promise to Precision in Clinical Trials
Thank You
Corporate Headquarter:
1-121/1, Miyapur, Hyderabad 500 049 INDIA
Dr. Yati Chugh
Chief Executive Officer
yati.c@axisclinicals.com
Abhijit Chaudhari
Director-Business Development
abhijit.chaudhari@axisclinicals.com
Sidharth Mishra
Director-Business Development (U.S.)
sidharth.m@axisclinicals.com
A Promise to Precision in Clinical Trials

More Related Content

What's hot

management of clinical trials: sponser perspective from falgun vyas
management of clinical trials: sponser perspective from falgun vyasmanagement of clinical trials: sponser perspective from falgun vyas
management of clinical trials: sponser perspective from falgun vyas
Falgun Vyas
 
MEDICAL DEVICE DEVELOPMENT_0327
MEDICAL DEVICE DEVELOPMENT_0327MEDICAL DEVICE DEVELOPMENT_0327
MEDICAL DEVICE DEVELOPMENT_0327
Robert Stathopulos
 
Site & investigator selection
Site & investigator selectionSite & investigator selection
Site & investigator selection
Mukesh Jaiswal
 

What's hot (20)

Investigational new drug
Investigational new drugInvestigational new drug
Investigational new drug
 
ICH ethics and animal experimentation
ICH ethics and animal experimentationICH ethics and animal experimentation
ICH ethics and animal experimentation
 
Clinical Pharmacology in Orphan Drug Development
Clinical Pharmacology in Orphan Drug DevelopmentClinical Pharmacology in Orphan Drug Development
Clinical Pharmacology in Orphan Drug Development
 
Site qualification visit
Site qualification visitSite qualification visit
Site qualification visit
 
Drug Development Project Mgmt
Drug Development Project MgmtDrug Development Project Mgmt
Drug Development Project Mgmt
 
Risk Based Monitoring in Clinical Trials - Impact on Sites
Risk Based Monitoring in Clinical Trials - Impact on SitesRisk Based Monitoring in Clinical Trials - Impact on Sites
Risk Based Monitoring in Clinical Trials - Impact on Sites
 
plasma master file in European countries and requirements in letter of intent...
plasma master file in European countries and requirements in letter of intent...plasma master file in European countries and requirements in letter of intent...
plasma master file in European countries and requirements in letter of intent...
 
Ich guidelines ppt
Ich guidelines pptIch guidelines ppt
Ich guidelines ppt
 
management of clinical trials: sponser perspective from falgun vyas
management of clinical trials: sponser perspective from falgun vyasmanagement of clinical trials: sponser perspective from falgun vyas
management of clinical trials: sponser perspective from falgun vyas
 
Drug Development Life Cycle - Costs and Revenue
Drug Development Life Cycle - Costs and RevenueDrug Development Life Cycle - Costs and Revenue
Drug Development Life Cycle - Costs and Revenue
 
Real-World Evidence: The Future of Data Generation and Usage
Real-World Evidence: The Future of Data Generation and UsageReal-World Evidence: The Future of Data Generation and Usage
Real-World Evidence: The Future of Data Generation and Usage
 
Inspection Findings in Clinical Trials
Inspection Findings in Clinical TrialsInspection Findings in Clinical Trials
Inspection Findings in Clinical Trials
 
CLINICAL DATA MANAGEMENT.pptx
CLINICAL DATA MANAGEMENT.pptxCLINICAL DATA MANAGEMENT.pptx
CLINICAL DATA MANAGEMENT.pptx
 
USFDA Over View
USFDA  Over ViewUSFDA  Over View
USFDA Over View
 
Basics Of Pharmacovigilance
Basics Of PharmacovigilanceBasics Of Pharmacovigilance
Basics Of Pharmacovigilance
 
Handling Third Party Vendor Data_Katalyst HLS
Handling Third Party Vendor Data_Katalyst HLSHandling Third Party Vendor Data_Katalyst HLS
Handling Third Party Vendor Data_Katalyst HLS
 
Medical writing organisation
Medical writing organisationMedical writing organisation
Medical writing organisation
 
Understanding FDA Requirements Medical Devices
Understanding FDA Requirements Medical DevicesUnderstanding FDA Requirements Medical Devices
Understanding FDA Requirements Medical Devices
 
MEDICAL DEVICE DEVELOPMENT_0327
MEDICAL DEVICE DEVELOPMENT_0327MEDICAL DEVICE DEVELOPMENT_0327
MEDICAL DEVICE DEVELOPMENT_0327
 
Site & investigator selection
Site & investigator selectionSite & investigator selection
Site & investigator selection
 

Similar to AXIS Clinicals Corporate Presentation

Sitec Presentation 140915
Sitec Presentation 140915Sitec Presentation 140915
Sitec Presentation 140915
Sitec Labs
 
Enem Nostrum Presentation
Enem Nostrum PresentationEnem Nostrum Presentation
Enem Nostrum Presentation
Amit Khandagale
 
Discovering New Innovations in Oncology
Discovering New Innovations in OncologyDiscovering New Innovations in Oncology
Discovering New Innovations in Oncology
InsideScientific
 
Updated capabilities overview1
Updated  capabilities overview1Updated  capabilities overview1
Updated capabilities overview1
malbergo
 

Similar to AXIS Clinicals Corporate Presentation (20)

Sitec Presentation 140915
Sitec Presentation 140915Sitec Presentation 140915
Sitec Presentation 140915
 
Best babe cro in india
Best babe cro in indiaBest babe cro in india
Best babe cro in india
 
KPSCS CORPORATE PRESENTATION
KPSCS CORPORATE PRESENTATIONKPSCS CORPORATE PRESENTATION
KPSCS CORPORATE PRESENTATION
 
Clinical Research Organization Services | Contract Research Company - Pepgra
Clinical Research Organization Services | Contract Research Company - PepgraClinical Research Organization Services | Contract Research Company - Pepgra
Clinical Research Organization Services | Contract Research Company - Pepgra
 
Presentation China And Usa July 2011
Presentation   China And Usa July 2011Presentation   China And Usa July 2011
Presentation China And Usa July 2011
 
Alchemy Clinical Research
Alchemy Clinical ResearchAlchemy Clinical Research
Alchemy Clinical Research
 
Clinical Trials
Clinical TrialsClinical Trials
Clinical Trials
 
Strand SmartLab - Enabling Precision Medicine at community Hospitals
Strand SmartLab - Enabling Precision Medicine at community HospitalsStrand SmartLab - Enabling Precision Medicine at community Hospitals
Strand SmartLab - Enabling Precision Medicine at community Hospitals
 
Innovative Solutions to Advance Immune-Mediated Inflammatory Disease Drug Dev...
Innovative Solutions to Advance Immune-Mediated Inflammatory Disease Drug Dev...Innovative Solutions to Advance Immune-Mediated Inflammatory Disease Drug Dev...
Innovative Solutions to Advance Immune-Mediated Inflammatory Disease Drug Dev...
 
BioDuro
BioDuro BioDuro
BioDuro
 
Qps Presentation
Qps PresentationQps Presentation
Qps Presentation
 
What Is Care?
What Is Care?What Is Care?
What Is Care?
 
Hcr Part1
Hcr Part1Hcr Part1
Hcr Part1
 
Mtr corporate
Mtr corporateMtr corporate
Mtr corporate
 
Clinical Trials
Clinical TrialsClinical Trials
Clinical Trials
 
Enem Nostrum Presentation
Enem Nostrum PresentationEnem Nostrum Presentation
Enem Nostrum Presentation
 
Discovering New Innovations in Oncology
Discovering New Innovations in OncologyDiscovering New Innovations in Oncology
Discovering New Innovations in Oncology
 
Cr and opportunities by bhumika
Cr and opportunities by bhumikaCr and opportunities by bhumika
Cr and opportunities by bhumika
 
Updated capabilities overview1
Updated  capabilities overview1Updated  capabilities overview1
Updated capabilities overview1
 
Clinical Research Presentation
Clinical Research PresentationClinical Research Presentation
Clinical Research Presentation
 

Recently uploaded

Recently uploaded (20)

CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptxCURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
 
1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf
1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf
1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf
 
Is preeclampsia and spontaneous preterm delivery associate with vascular and ...
Is preeclampsia and spontaneous preterm delivery associate with vascular and ...Is preeclampsia and spontaneous preterm delivery associate with vascular and ...
Is preeclampsia and spontaneous preterm delivery associate with vascular and ...
 
Presentació "Advancing Emergency Medicine Education through Virtual Reality"
Presentació "Advancing Emergency Medicine Education through Virtual Reality"Presentació "Advancing Emergency Medicine Education through Virtual Reality"
Presentació "Advancing Emergency Medicine Education through Virtual Reality"
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
 
Retinal consideration in cataract surgery
Retinal consideration in cataract surgeryRetinal consideration in cataract surgery
Retinal consideration in cataract surgery
 
Gauri Gawande(9) Constipation Final.pptx
Gauri Gawande(9) Constipation Final.pptxGauri Gawande(9) Constipation Final.pptx
Gauri Gawande(9) Constipation Final.pptx
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
 
linearity concept of significance, standard deviation, chi square test, stude...
linearity concept of significance, standard deviation, chi square test, stude...linearity concept of significance, standard deviation, chi square test, stude...
linearity concept of significance, standard deviation, chi square test, stude...
 
Antiplatelets in IHD, Dose Duration, DAPT vs SAPT
Antiplatelets in IHD, Dose Duration, DAPT vs SAPTAntiplatelets in IHD, Dose Duration, DAPT vs SAPT
Antiplatelets in IHD, Dose Duration, DAPT vs SAPT
 
Scientificity and feasibility study of non-invasive central arterial pressure...
Scientificity and feasibility study of non-invasive central arterial pressure...Scientificity and feasibility study of non-invasive central arterial pressure...
Scientificity and feasibility study of non-invasive central arterial pressure...
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
 
Compare home pulse pressure components collected directly from home
Compare home pulse pressure components collected directly from homeCompare home pulse pressure components collected directly from home
Compare home pulse pressure components collected directly from home
 
Anuman- An inference for helpful in diagnosis and treatment
Anuman- An inference for helpful in diagnosis and treatmentAnuman- An inference for helpful in diagnosis and treatment
Anuman- An inference for helpful in diagnosis and treatment
 
Relationship between vascular system disfunction, neurofluid flow and Alzheim...
Relationship between vascular system disfunction, neurofluid flow and Alzheim...Relationship between vascular system disfunction, neurofluid flow and Alzheim...
Relationship between vascular system disfunction, neurofluid flow and Alzheim...
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
 
Effects of vaping e-cigarettes on arterial health
Effects of vaping e-cigarettes on arterial healthEffects of vaping e-cigarettes on arterial health
Effects of vaping e-cigarettes on arterial health
 
Aptopadesha Pramana / Pariksha: The Verbal Testimony
Aptopadesha Pramana / Pariksha: The Verbal TestimonyAptopadesha Pramana / Pariksha: The Verbal Testimony
Aptopadesha Pramana / Pariksha: The Verbal Testimony
 
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
 

AXIS Clinicals Corporate Presentation

  • 1. A Promise to Precision in Clinical Trials
  • 2. Vision / Mission • To be the preferred, trusted and valued Clinical development partner for global pharmaceutical & biotechnology companies. • Known as a Integrated health service provider of choice. • Deliver sophisticated clinical research services without compromising quality or timelines. A Promise to Precision in Clinical Trials
  • 3. A Promise to Precision in Clinical Trials Value Based Leadership : Our mission outlines the value that provides the foundation to perform as a Global service provider and as individual employees so that we can continue to put the needs of the Customers we serve first. Integrity : We do what is right. a) We are committed to conduct our business with individual and organizational Integrity. b) We comply with Local and International laws. c) We are reliable, honest and trustworthy in our dealings. Responsibility : We hold ourselves accountable for our actions. a) We take personal responsibility in everything that we do and we lead by example. b) We treat our Organization's reputation as our own. c) We are committed to a culture of shared responsibility that promotes high performance. Our Core Values
  • 4. A Promise to Precision in Clinical Trials a) Speed : We will speed you to the next milestone, while avoiding the bumps in the road. Because the faster you reach each milestone, the faster your compound can be advanced to next stage. b) Quality : We are passionate about what we do and want our name to stand for Excellence. We are determined to be an example that the industry aspires to follow. c) Customer Focus : We build long lasting, collaborative relationship with our customers and work with them as thought partners. c) Disciplined Timelines : We value the importance of time and adhere to our commitments. Your Preferred Partner of Choice – Why ?
  • 5. A Promise to Precision in Clinical Trials Leading Global Clinical Research organization accelerating the Drug Development.  Established in Sept. 2004.  Central Headquarters at Hyderabad, India.  Facilities in 3 Countries (India, Mexico and Thailand) and more than 400+ professionals operating worldwide.  Fully Compliant with ICH GCP, ICMR, Mexican COFEPRIS, Thai FDA and Schedule – Y Guidelines.  Combined Clinical bed Strength of 500 +, supported by 22 LC-MS/MS machines, with more than 275+ validated analytical methods.  More than 50,000 active study participants in global database.  Over 80% business repeat business. Overview
  • 6. A Promise to Precision in Clinical Trials Experience:  8+ years of Biopharmaceutical experience for Global clients.  50+ Pharma and Biotech Sponsors all over the globe.  1550+ successful clinical studies. Consistency:  Less than 5% attrition YOY.  More than 80% Repeat Business. Global Footprints :  Operations : India, Mexico and Thailand.  Offices in India, USA, Mexico and Thailand. Overview…
  • 7. 2007 2008 2009 2010 2011 2013 ANVISA- Brazil : ANVISA Certification. US-FDA : October. US-FDA : March. UK-MHRA : February. FRENCH-AFSSAPS : June. ANVISA- Brazil : October. US-FDA : October. US-FDA : May. US-FDA : June. US-FDA : February. US-FDA : March. US-FDA : October. Turkey-MOH : December. ANVISA- Brazil : August. UK-MHRA : October. ANVISA – Brazil : August USFDA : August Global Regulatory Accreditations - Milestones A Promise to Precision in Clinical Trials NABL : Accreditation. ANVISA – Brazil : October. USFDA : October. 2012
  • 8. Capabilities / Expertise @ AXIS PK / PD studies  Bioequivalence / Bioavailability studies  Pharmacokinetic / Pharmacodynamic studies in Healthy subjects  Special / Patient Population studies.  Food effect / Drug – Drug Interaction studies.  Proof of Concept studies.  End-to End Service  - Protocol to Report  Project Management  Final submission Report (eCTD / ICH E3) Clinical Research  Phase II- IV trials  PK / PD Studies in patients  Feasibility Studies  Project Planning and Setup  Study Design and Protocol Writing  Regulatory Approvals  Design & Development of CRF / eCRF  Project Management  Site/Investigator Identification and Selection  Site Monitoring  Site Management  Quality Assurance/Audit Services A Promise to Precision in Clinical Trials
  • 9. Biostatistics & Medical Writing  Sample Size and Power Calculation  Medical writing and literature search  Providing Statistical Inputs during Protocol Designing  Randomization  Statistical Analysis Plan (SAP)  SAS Programming and Validation  Interim Analysis  Statistical Report Clinical Data Management  Data Management Plan  Database Design & Development  Double-Data Entry  Query Management  Medical Coding, SAE Data Reconciliation  Edit, Validation and Design check programming  Data Validation  Data Cleaning  Quality Control and Data Quality Audits  Database Lock and Export to SAS  Clean Data Files  Project Data Archival and Storage Capabilities / Expertise @ AXIS … A Promise to Precision in Clinical Trials
  • 10. Capabilities / Expertise @ AXIS … Stand Alone Services  Regulatory Services.  Central Reference Lab Services.  Bio Analytical Services.  Metal Ion analysis.  Biostatistical & Medical Writing.  Quality Assurance.  Clinical Data Management. A Promise to Precision in Clinical Trials
  • 11. Regulatory Inspections & Approvals  Successfully completed over 38 regulatory audits by Indian and International regulatory bodies  Completed 50+ National and International sponsor audits Canada Turkey MOH Credentials WHO Australia US FDA UK MHRA Brazil ANVISA France AFSSAPS Mexico MOHNABL India South Africa Product Approvals A Promise to Precision in Clinical Trials Malaysia
  • 12. US, 973 Europe, 300 Brazil, 67 Canada, 101 Australia, 62 Korea, 25 WHO, 10 Turkey, 12 Russia, 3 India, 3 Studies Completed = 1550+ Bio-studies Experience : Geographical Submissions A Promise to Precision in Clinical Trials
  • 13. Clinical Pharmacology India  292 Beds arranged in 7 study areas in 2 locations .  1,90,000 sq. ft area.  7 Intensive Care Units with cardiac monitoring.  Audited &/or accredited by US FDA, UK MHRA, Brazilian ANVISA, India (DCGI), AFSSAPS, NABL and ISO 9001:2000.  World-class infrastructure to support clinical activities.  18 LC-MS/MS & 1 ICP-OES for bioanalysis.  Capacity to handle approx. 2000 Clinical dosings / month.  Capability to analyze approx. 35,000 samples / month. A Promise to Precision in Clinical Trials
  • 14. Clinical Pharmacology Mexico  100 Beds arranged in 3 study areas.  Intensive Care Units with cardiac monitoring.  Dedicated Clinical Reference Lab.  Approved by Cofepris (Mexican Regulatory Agency) for Clinical and Bioanalytical operations.  World-class infrastructure to support the Latin America market & other Regulated markets.  4 LC-MS/MS for bioanalysis.  Independent Project Management Group. A Promise to Precision in Clinical Trials
  • 15. Clinical Pharmacology Thailand  72 Beds arranged in 6 study areas.  Hospital setup  Intensive Care Units with cardiac monitoring.  World-class infrastructure to support clinical activities in SE Asian countries.  Capabilities to conduct and monitor the Phase II – IV studies A Promise to Precision in Clinical Trials
  • 16.  Testing @ ACRL  Hematology and Coagulation Assays  Biochemistry  Clinical Pathology  Immunoassays  Histopathology  NABL (National Accreditation Board for Testing and Calibration Laboratories) accredited laboratory  Audited by Brazil ANVISA & UK MHRA  Services for Clinical Trials having multiple sites & CROs (Stand Alone Services also offered). Clinical Reference Laboratory A Promise to Precision in Clinical Trials
  • 17.  18 LC-MS/MS (SCIEX API 2000, 3000, 3200, 4000, 4000Q and 5000)  5 HPLC-UV/Fluorescent Detectors.  1 ICP-OES for Trace Metal Analysis.  275+ validated assays.  Quantitative analysis of parent drugs and their metabolites in a variety of biological matrices.  Networked Chromatographic Data Management (Scientific Data Management System)  Solid Phase Extraction Systems.  Nitrogen Evaporators.  Capability to analyse > 35,000 samples/month. Bioanalytical Lab A Promise to Precision in Clinical Trials
  • 18.  Critical assays developed First-in-Asia for small molecules  Conjugated Estrogen  Esterified Estrogens  Estradiol  Ethinyl Estradiol & Levonorgestrol  Many combinations of Oral Contraceptives  First-in-world assays for small & large molecules  Loteprednol in Aqueous Humor  Dexamethasone in Aqueous Humor  Testosterone in serum  Critical assay in development and validation stage for large molecules  Insulin  Glucagon  Enoxaparin Bioanalytical Lab … A Promise to Precision in Clinical Trials
  • 19. Expertise (Formulations & Therapeutic Areas) Formulations  Oral Solids – Capsules, Tablets, Softgels, Granules, ODT, ODP, Modified Release  Liquid Orals  Parenterals  Transdermal patches  Topical Gel  Cream  Inhalers  Nasal Sprays Therapeutic Areas  Antibiotic/ Antimicrobial  Antidepressant  Antiepileptic  Antiretroviral  Hormone  Hypoglycemic agents  Lipid lowering agents  Muscle relaxants  NSAIDs  Narcotics  Oral contraceptive  Psychotropic agents A Promise to Precision in Clinical Trials
  • 20. Quality Systems @ AXIS  A 30 member dedicated team reporting to QA Head.  Quality Control (QC) Procedures in place apart from Quality Assurance (QA) Procedures.  All activities are subjected to rigorous review for Quality Assurance including  Clinical (over 50 SOP’s)  Bio-analytical  PK / Stats / Reporting  Internal Audits by QA team for Area Specific SOP compliance.  In-house capabilities to perform Site Audits, Systems / Process Audit, Vendor Audit.  Document Audits (Protocol, Clinical Study Report & essential Clinical Trial documents).  All QA systems are compliant with all applicable local & international regulations. A Promise to Precision in Clinical Trials
  • 21. Clinical Experience and Capabilities  Summary Protocol / Synopsis  Study Feasibility Analysis  Study Design  Medical Writing and Protocol Development  Project Planning and Setup  Regulatory Approvals  Design & Development of CRF / eCRF  Site/Investigator Identification and Selection  Site Management  Site Monitoring  Project Management  Clinical Data Management  Clinical Study Reports  Quality Assurance / Audit Services A Promise to Precision in Clinical Trials
  • 22. Clinical Research (Phase II –IV)  Phase 2-4 Clinical Trials (New Chemical Entities)  >150 sites  >200 Investigators  Oncology, CNS, Cardiology, Gastrointestinal, Orthopedic, Ophthalmology, Endocrinology & Metabolism  505(b)(2) Clinical Studies.  Clinical End Point Studies.  Patient Population PK Studies, A Promise to Precision in Clinical Trials
  • 23. Experience – Clinical Trials Sr. No. Therapeutic Segment Study phase Patients / Sites Current status 1. Allergic conjunctivitis Phase III 514; 10 sites Recruitment expected to complete in 90 days 2. Schizophrenia Clinical PK study 28; 2 sites Recruitment completed within 50 days 3. Schizophrenia Clinical PK study 40; 3 sites Recruitment completed within 81 days 4. Schizophrenia Clinical PK study 26; 4 sites Recruitment completed within 79 days 5. Epilepsy Clinical PK study 34; 2 sites Recruitment completed within 170 days 6. Anemia in CKD Phase IIa 180; 8 sites Recruitment completed within 120 days 7. Schizophrenia Clinical PK study 42; 4 sites Recruitment completed within 75 days A Promise to Precision in Clinical Trials
  • 25. AXIS’ Investigator & Sites relationship Clinical Research – Potential Investigator Database A Promise to Precision in Clinical Trials
  • 26. Clinical Data Management & Biostatistics  Oracle Clinical® v4.6 with Remote Data Capture  Project Specific Clinical Data Management Plan  Customized Database Design & Development  Independent Double-Data Entry  Query Management  Medical Coding, SAE Data Reconciliation  Edit, Validation and Design check  Data Validation  Data Cleaning  Quality Control and Data Quality Audits  Database Lock and Export to SAS  Documentation CDM Report A Promise to Precision in Clinical Trials
  • 27.  Project Management Group (PMG) : Dedicated Project Managers are assigned to each Client to ensure the timely execution of the projects at AXIS Clinicals. Back up Project Managers help to maintain the continuity.  QA Department : 30 experienced personnel to maintain Quality of the highest standards.  HR / Training Department: A team of 4 people in the Training Department ensures the Inductions, On Job Trainings, Refresher Trainings and arranging External Trainings for the AXIS employees.  Validation : AXIS has a dedicated team for Validation and the maintenance of Scientific equipment is done on a regular basis by the GLP Engineers.  Pharmacy : Each of the Clinical Units of AXIS has Dedicated Pharmacists for the IMP Management Support Teams at Axis A Promise to Precision in Clinical Trials
  • 28. Management Team Michael Padvaiskas Ackerman President - Mexico Operations Dr. A. Jayachandra Reddy Sr. V.P – Clinical Pharmacology Dr. Yati Chugh Chief Executive Officer B. Phani Bhushana Reddy Sr. V.P – Bioanalytical Operations A Promise to Precision in Clinical Trials
  • 29. Someswar Korla Head – PK/Stats/Medical Writing Sathish Munaga Head – Quality Assurance Abhijit Chaudhari Director – Business Dev. (India / ROW) Sidharth Mishra Director – Business Dev. (U.S.A) Dr. Subhra Lahiri AVP – Clinical Research A Promise to Precision in Clinical Trials Dr. Kshitij Soni Director – ASEAN Operations
  • 30.  End to End service provider with experienced Clinical research professionals and Excellent infrastructure.  Impressive Accreditations from International Regulatory Bodies.  Successful Regulatory Inspections track record.  Teams with Rich professional Experience.  Expertise in various Therapeutic segment.  Access to Patient’s in major therapeutic areas.  Fast and excellent Turn around time.  Competitive Pricing as compared to Industry Peers.  AXIS can help you to file FTF application in 18 – 20 days.  Top 5 International Generic companies among the list of Client’s. The AXIS Edge A Promise to Precision in Clinical Trials
  • 31. Thank You Corporate Headquarter: 1-121/1, Miyapur, Hyderabad 500 049 INDIA Dr. Yati Chugh Chief Executive Officer yati.c@axisclinicals.com Abhijit Chaudhari Director-Business Development abhijit.chaudhari@axisclinicals.com Sidharth Mishra Director-Business Development (U.S.) sidharth.m@axisclinicals.com A Promise to Precision in Clinical Trials